WO2023214388 - NOVEL CD200 FUSION PROTEINS
National phase entry:
Publication Number
WO/2023/214388
Publication Date
09.11.2023
International Application No.
PCT/IB2023/054722
International Filing Date
05.05.2023
Title **
[English]
NOVEL CD200 FUSION PROTEINS
[French]
NOUVELLES PROTÉINES DE FUSION CD200
Applicants **
DUCENTIS BIOTHERAPEUTICS LIMITED
Inventors
ASHFIELD, Rebecca
Priority Data
2206673.2
06.05.2022
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2561 | |
| EPO | Filing, Examination, Granting | 15035 | |
| Japan | Filing, Examination, Granting | 2543 | |
| South Korea | Filing, Examination, Granting | 2806 | |
| USA | Filing, Examination, Granting | 6740 |
Total:
29,685
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to fusion proteins comprising a mutated CD200 portion comprising K130Y and I131Y mutations which binds with greater affinity to the human CD200 receptor than wild-type CD200, directly fused to a non-CD200 IgG4 Fc fragment which comprises S228P, M428L and N434S mutations and deletion of the first 5 amino acids. The invention also relates to a polynucleotide encoding the fusion protein, a pharmaceutical composition comprising it and uses thereof.[French]
L'invention concerne des protéines de fusion comprenant une partie CD200 mutée comprenant des mutations K130Y et I131Y qui se lient avec une plus grande affinité au récepteur CD200 humain que CD200 de type sauvage, directement fusionnées à un fragment Fc IgG4 non CD200 qui comprend des mutations S228P, M428L et N434S et une délétion des 5 premiers acides aminés. L'invention concerne également un polynucléotide codant pour la protéine de fusion, une composition pharmaceutique le comprenant et des utilisations associées.